Using virtual patient cohorts to uncover immune response differences in cancer and immunosuppressed COVID-19 patients
PLOS Computational Biology · 2025
DOI: 10.1371/journal.pcbi.1013170 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Computational Biology, 2025. Verfasst von Sonia T Gazeau und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sainte-Justine University Hospital Research Centre, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: COVID-19, Neoplasms, Immunocompromised Host. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Université de Montréal, Fonds de recherche du Québec – Nature et technologies.
Abstract (Originalsprache)
The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) resulted in millions of deaths globally. Adults with immunosuppression (e.g., solid organ transplant recipients) and those undergoing active cancer treatments experience worse infections and more severe COVID-19. It is difficult to conduct clinical studies in these populations, resulting in a restricted amount of data that can be used to relate mechanisms of immune dysfunction to COVID-19 outcomes in these vulnerable groups. To study immune dynamics after infection with SARS-CoV-2 and to investigate drivers of COVID-19 severity in individuals with cancer and immunosuppression, we adapted our mathematical model of the immune response during COVID-19 and generated virtual patient cohorts of cancer and immunosuppressed patients. The cohorts of plausible patients recapitulated available longitudinal clinical data collected from patients in Montréal, Canada area hospitals. Our model predicted that both cancer and immunosuppressed virtual patients with severe COVID-19 had decreased CD8 + T cells, elevated interleukin-6 concentrations, and delayed type I interferon peaks compared to those with mild COVID-19 outcomes. Additionally, our results suggest that cancer patients experience higher viral loads (however, with no direct relation with severity), likely because of decreased initial neutrophil counts (i.e., neutropenia), a frequent toxic side effect of anti-cancer therapy. Furthermore, severe cancer and immunosuppressed virtual patients suffered a high degree of tissue damage associated with elevated neutrophils. Lastly, parameter values associated with monocyte recruitment by infected cells were found to be elevated in severe cancer and immunosuppressed patients with respect to the COVID-19 reference group. Together, our study highlights that dysfunctions in type I interferon and CD8 + T cells are key drivers of immune dysregulation in COVID-19, particularly in cancer patients and immunosuppressed individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Sainte-Justine University Hospital Research Centre, Montréal, Québec, Canada.
- Department of Mathematics and Statistics, Université de Montréal, Montréal, Québec, Canada.
- University of California, San Francisco, California, United States of America.
- Research Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada.
- Division of Infectious Diseases, Department of Medicine, Lausanne University Hospital (CHUV) and Université de Lausanne, Lausanne, Switzerland.
- Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
ORCID-Profile: Sonia T Gazeau, Penelope A Morel
Förderung
- NIAID NIH HHS
- Université de Montréal
- Fonds de recherche du Québec – Nature et technologies
- National Institute of Health
- Natural Sciences and Engineering Research Council (NSERC) of Canada and the Public Health Agency of Canada
- Natural Sciences and Engineering Research Council (NSERC) DISCOVERY
- COVID-19 immunity task force and the Canadian Institute of Health research
- Fonds de Recherche du Québec - Santé
Zitieren
APA
Gazeau, S. T., Deng, X., Brunet-Ratnasingham, E., Kaufmann, D. E., Larochelle, C., Morel, P. A., Heffernan, J. M., Davis, C. L., Smith, A. M., Jenner, A. L., & Craig, M. (2025). Using virtual patient cohorts to uncover immune response differences in cancer and immunosuppressed COVID-19 patients. PLOS Computational Biology. https://doi.org/10.1371/journal.pcbi.1013170
Vancouver
Gazeau ST, Deng X, Brunet-Ratnasingham E, Kaufmann DE, Larochelle C, Morel PA, et al. Using virtual patient cohorts to uncover immune response differences in cancer and immunosuppressed COVID-19 patients. PLOS Computational Biology. 2025. doi:10.1371/journal.pcbi.1013170
BibTeX
@article{Gazeau2025,
author = {Gazeau, Sonia T and Deng, Xiaoyan and Brunet-Ratnasingham, Elsa and Kaufmann, Daniel E and Larochelle, Catherine and Morel, Penelope A and Heffernan, Jane M and Davis, Courtney L and Smith, Amber M and Jenner, Adrianne L and Craig, Morgan},
title = {Using virtual patient cohorts to uncover immune response differences in cancer and immunosuppressed COVID-19 patients},
journal = {PLOS Computational Biology},
year = {2025},
doi = {10.1371/journal.pcbi.1013170}
}
EUVIMED